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The use of glucocorticoids to treat individuals with con-
genital adrenal hyperplasia (CAH) was ﬁrst reported by
both Wilkins and Bartter in 1950. Since that time, the care
of these patients has improved dramatically, and through
the eﬀorts of dedicated medical researchers, it continues to
improve today. With early detection by newborn screening,
initiation of treatment in infants with salt-wasting CAH has
led to reduced morbidity and mortality. This special issue
of the International Journal of Pediatric Endocrinology is
intended to review the state of the art in medical treatment
and psychological management as well as evaluations of the
outcomes of patients with CAH.
We begin with a summary of the recent Endocrine Soci-
ety Clinical Practice Guideline, which provides an overview
of the diagnosis and treatment of CAH across the lifespan.
We then move on to discussions concerning the diagnosis
and treatment of nonclassic CAH and the management of
the various forms of CAH in the adult patient. Although
hydrocortisone has been the treatment of choice for many
years in children with CAH, more potent glucocorticoids
such as dexamethasone are considered by some to be supe-
rior. Aseriesofarticlesaddresses thechoiceofglucocorticoid
and the timing of administration. The section on treatment
ﬁnishes with discussions of mineralocorticoid replacement
and newer therapeutic modalities.
The next section deals with psychological management,
speciﬁcally with regards to psychosocial stress in families
of aﬀected patients. We then move on to models of care
provision, including establishment of a medical home,
multidisciplinary care, and a discussion of the roles of
support and advocacy groups in the care of individuals with
CAH.
Assessments of treatment outcomesare criticalfor eﬀorts
to improve care. This issue ﬁnishes with a series of papers
reviewing CAH outcomes, including growth in children,
gynecologic and reproductive issues in women, bone health,
and psychological, cognitive, and gender identity outcomes.
The guest editors hope that this issue will, in a small
way, advance their understanding of CAH and stimulate
additional research and multidisciplinary teamwork, with
the goal of improving the lives of those aﬀected with this
potentially devastating condition.
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